Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B007 in Primary Membranous Nephropathy
NCT05668403Phase 1Recruiting
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of B007 in primary membranous nephropathy (PMN) (3 arms), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Primary endpoints: Dose Limiting Toxicity at 1 year and Incidence of Treatment-Emergent Adverse Events at 2 years. Started Mar 2023; status: recruiting.
02
Drugs
B007
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT05668403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668403.